ReviewBritish journal of clinical pharmacology2010
Warfarin and vitamin K intake in the era of pharmacogenetics.
Review in British journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.Clinical pharmacology and therapeutics · 2012Pooled it
- Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.British journal of clinical pharmacology · 2015Trial
- Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.Journal of thrombosis and thrombolysis · 2014Trial
- Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients.Journal of thrombosis and thrombolysis · 2026Article
- Changes in quality of vitamin K antagonist treatment and clinical outcomes during Ramadan: a Dutch population-based cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- Prolonged Prothrombin Time due to Drug-Drug Interaction of Warfarin after the Change from Bosentan to Macitentan: A Case of Pharmacist Intervention in the Outpatient Clinic.The Kobe journal of medical sciences · 2025Article
- The Future of Pharmacogenomics: Integrating Epigenetics, Nutrigenomics, and Beyond.Journal of personalized medicine · 2024Review
- Article
- DFinder: a novel end-to-end graph embedding-based method to identify drug-food interactions.Bioinformatics (Oxford, England) · 2023Article
- Differences in the Perception of Dietary Supplements between Dietary Supplement/Medicine Users and Non-Users.Nutrients · 2022Article
- Article
- The Challenge and Importance of Integrating Drug-Nutrient-Genome Interactions in Personalized Cardiovascular Healthcare.Journal of personalized medicine · 2022Review
- Anticoagulation in Patients With Chronic Liver Disease.Gastroenterology & hepatology · 2021Article
- Frequently Asked Questions about Thrombosis during COVID-19 Pandemic.TH open : companion journal to thrombosis and haemostasis · 2020Article
- Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs.Theranostics · 2020Review
- Predicting and Understanding the Human Microbiome's Impact on Pharmacology.Trends in pharmacological sciences · 2019Review
- New versus Old Oral Anticoagulants: How Can We Set the Scale Needle? Considerations on a Case Report.Medicina (Kaunas, Lithuania) · 2019Article
- The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.Arrhythmia & electrophysiology review · 2018Article
- New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism.Biomolecules & therapeutics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The considerable variability in the warfarin dose-response relationship between individuals, is explained mainly by genetic variation in its major metabolic (CYP2C9) and target (VKORC1) enzymes. Despite the predominance of pharmacogenetics, environmental factors also affect the pharmacokinetics and pharmacodynamics of warfarin, and are often overlooked. Among these factors, dietary and supplemental vitamin K consumption is a controllable contributor to within-, and between-patient variability of warfarin sensitivity. In this commentary we review the current role of vitamin K in warfarin anticoagulation therapy, with emphasis on the following: 1 The effect of dietary and supplemental vitamin K on warfarin anticoagulation, beyond the impact of genetic variability in CYP2C9 and VKORC1. We deal separately with the effects of vitamin K on warfarin dose requirements during the induction of therapy, as opposed to its effect on stability of anticoagulation control during maintenance therapy. 2 The role of vitamin K supplementation in warfarin treated patients with vitamin K deficiency as well as in patients with unstable warfarin anticoagulation, and 3 The role of therapeutic vitamin K in cases of warfarin over-anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.